Predictors of Intravenous Ketamine Response in TRD

NCT ID: NCT05625555

Last Updated: 2024-02-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-19
• Study Completion Date: 2025-02-28

Brief Summary

For patients with treatment-resistant depression (TRD), a single low dose of intravenous (IV) ketamine can help relieve symptoms as quickly as 24 hours later.

The main problem with IV ketamine for TRD is that the effect is short-lived, lasting only days to 1 or 2 weeks. Furthermore, IV ketamine is a resource-intensive treatment, and the safety of long-term, repeated use for depression is unknown. To provide this treatment in a safe and cost-effective way, Investigators must allocate it efficiently to those patients who have the greatest need and probability of benefit. Therefore, this project aims to find clinical features (signs, symptoms, and parts of a patient's history) that will help predict which patients are most likely to respond to a single dose of IV ketamine for TRD. This will help guide patient selection and triaging.

Investigators will recruit 40 participants with TRD over one year, and randomize them to one of two conditions (ketamine followed by an active placebo 3-weeks later, or vice versa). With clinical data collected through detailed interviews, questionnaires, actigraphy, speech sampling, electroencephalography (EEG), and computerized tasks, this study design will let us evaluate how well such factors predict (A) rapid response at 24-hours, and (B) sustained response at 7 and 14 days.

Detailed Description

Study Design:

This will be a randomized, double-blinded, midazolam-controlled crossover trial. There is no perfect control agent for studies of subanaesthetic IV ketamine, but midazolam is generally thought to be superior to normal saline since it is not an antidepressant, yet is psychoactive and thus should better preserve blinding. Participants will undergo psychiatric assessment to establish diagnosis and determine suitability. After providing informed consent for participation, participants will wear a GENEActive accelerometer on the non-dominant wrist for the duration of the trial, beginning 21 days prior to the first infusion. Participants will complete a set of rating scales, anhedonia measures and computerized tasks. On Day 0 (infusion day), participants will receive either a single infusion of IV ketamine (KET) (KET; 0.5mg/kg over 40 minutes) or midazolam (MID) (MID; 30μg/kg over 40 minutes) diluted in 0.9% NaCl by an intravenous pump. Investigators will randomize infusion sequences in a 1-to-1 ratio: KET followed by MID (K→M) or vice versa (M→K). Infusions will be administered on Days 0 and 21, separated by a 20-day washout period. This duration balances the need to establish comparable baselines at each crossover phase and the ethical consideration of not allowing depressive symptoms to remain untreated for an unreasonable amount of time.

Investigators will obtain objective depression ratings with the Montgomery-Åsberg Depression Rating Scale (MADRS) on Days -1, 1, 7, 14, 20, 22, 28, 35, and 41. Participants will provide weekly self-ratings of depressive symptoms (using the Quick Inventory of Depressive Symptoms 16-item self-rated version; QIDS 16-SR). Weekly symptom monitoring will continue for 20 days following the second infusion. Anhedonia will be measured using both self-reported rating scale measures as well as behavioural task. Patients will provide self-ratings using the Snaith-Hamilton Pleasure Scale - 14 items (SHAPS), the Dimensional Anhedonia Rating Scale - 17 items (DARS), and Positive Valence System Scale - 21 items (PVSS-21). Several aspects of subjective sleep and circadian rhythms will be measured via self-report questionnaires. The Pittsburgh Sleep Quality Index (PSQI) will measure general sleep quality and sleep disturbance, and the Basic Language Morningness Scale (BALM) will be used to measure subjective chronotype (morningness-eveningness) of patients. Both will be completed by participants prior to the first infusion and 14 days after each infusion.

Participants will complete the Epworth Sleepiness Scale (ESS) to measure daytime sleepiness symptoms, as well as the Fatigue Scale Severity Scale (FSS) to measure symptoms of fatigue. Both ESS and FSS will be completed the day before and after each infusion, and every 7 days.

Study Groups:

Participants will receive either (A) 0.5mg/kg of ketamine hydrochloride or (B) 30μg/kg of MID diluted in 0.9 percent Sodium chloride (NaCl) over 40 minutes by an intravenous pump. The KET and MID doses are similar to those used in previous studies, and selected to minimize the possibility of unblinding. Participants must abstain from consuming grapefruit juice or benzodiazepines for 24 hours preceding the infusion since the former is a potent CYP3A4 inhibitor that may reduce the rate of midazolam and ketamine elimination, and the latter reduces the response to ketamine.

Conditions

Treatment Resistant Depression; Major Depressive Disorder; Bipolar Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Ketamine

Participants will be randomly assigned to receive Ketamine or Midazolam

Group Type: EXPERIMENTAL

Ketamine

Intervention Type: DRUG

IV Ketamine infusion 0.5mg/kg over 40 minutes

Midazolam

Participants will receive either Ketamine or Midazolam based on what they initially received

Group Type: ACTIVE_COMPARATOR

Midazolam

Intervention Type: DRUG

IV Midazolam infusion 30μg/kg over 40 minutes

Interventions

Ketamine

IV Ketamine infusion 0.5mg/kg over 40 minutes

Intervention Type: DRUG

Midazolam

IV Midazolam infusion 30μg/kg over 40 minutes

Intervention Type: DRUG

Other Intervention Names

Ketamine Hydrochloride; Kevlar; Midazolam Hydrochloride

Eligibility Criteria

Inclusion Criteria

• Able to fluently read in English with or without optical correction
• Ability to understand and comply with the study requirements

• This is determined by the investigators
• Provision of written informed consent
• Documented diagnosis of MDD or bipolar disorder meeting DSM-5 criteria (as confirmed by the Diagnostic Assessment Research Tool), currently in a single or recurrent episode without psychotic features
• Failure of at least two antidepressant medications from different pharmacological classes, as well as at least one augmentation agent, each of which must have been given at adequate doses for at least 6 weeks (recorded using the Antidepressant Treatment History Form - Short Form).

• Augmentation strategies include those listed in the 2016 Canadian Network for Mood and Anxiety Treatments (CANMAT) depression guidelines, including a 12-week course of cognitive behavioural therapy or interpersonal therapy.
• MADRS score of ≥25 at initial assessment and Day -1, and no more than 20% improvement between those visits.
• For premenopausal females who are currently sexually active with male partners:

• Negative urine pregnancy test at enrolment
• AND commitment to using an appropriate birth control method of their choice throughout the duration of the study, including

• Intrauterine device
• Oral contraceptive
• Long-term injectable contraceptive
• Double-barrier method
• Implant
• Dermal contraception
• Tubal ligation
• Abstinence from grapefruit juice consumption on the day of infusion
• Abstinence from benzodiazepine use within 24 hours of infusion
• Adherence to maintaining current antidepressant management

Exclusion Criteria

• Pregnant or breastfeeding
• Allergies to ketamine or midazolam
• Concomitant use of medications with the potential for clinically significant interactions with either ketamine or midazolam (e.g., monoamine oxidase inhibitors, methylene blue)

• Concomitant use of naltrexone or narcotics
• Positive urine drug screen or history of DSM-5 substance use disorder (except caffeine or nicotine)
• Previous or current benzodiazepine abuse history

• Previous ketamine use (therapeutic or recreational)
• History of electroconvulsive therapy
• Comorbid DSM-5 personality disorder with a major impact on mental status
• Secondary depressive disorders

• E.g. secondary to stroke, cancer, or other somatic pathology
• Subjects who will be starting psychotherapy during the trial period, or have only recently started psychotherapy within 2 months of the trial

• Evidence on history or chart review of any of the following:

• Epilepsy
• Any current or historical occurrence of renal disease

• Clinically significant abnormalities of liver function tests (total bilirubin, albumin, prothrombin time and international normalized ratio [PT/INR], gamma-glutamyl transferase [GGT], alkaline phosphatase [ALP]). Clinical significance of any abnormal liver function tests will be evaluated by the study anesthesiologists. Patients with clinically significant abnormalities suggesting hepatic disease will be excluded.
• Liver enzymes (AST, ALT) three times the upper normal limit at screening
• Exception: of history of acute kidney injury or transient reductions in glomerular filtration rate that have fully resolved for at least three months
• Any current or historical occurrence of hepatic disease

• Abnormal liver function tests
• Liver enzymes three times the upper normal limit at screening
• Exception: History of transient elevations of liver enzymes or reduction in liver function that have re-normalized for the past three months (as per criteria above concerning function/enzymes)
• Myocardial infarct within a year prior to initial randomization
• Chronic obstructive pulmonary disease
• Untreated obstructive sleep apnea
• Cerebrovascular disease (including history of cerebrovascular accident)
• Intracerebral structural lesions
• Viral hepatitis B or C
• Acquired immunodeficiency syndrome
• Interstitial cystitis
• Glaucoma
• Uncontrolled hypertension
• Decompensated heart failure
• Current uncorrected thyroid pathology or recent correction within 30 days (correction of thyroid function for longer than 1 month is admissible).
• Any unstable somatic pathology or clinically significant investigational abnormality (biochemical, ECG) that investigators believe would be negatively impacted by study procedures or that would negatively impact study procedures

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nova Scotia Health Authority

OTHER

Sponsor Role: collaborator

Abraham Nunes

OTHER

Sponsor Role: lead

Responsible Party

Abraham Nunes

Psychiatrist/Assistant Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Abraham Nunes, MD PhD MBA FRCPC

Role: PRINCIPAL_INVESTIGATOR

Nova Scotia Health Authority

Locations

Mood Disorders Program

Halifax, Nova Scotia, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Vanessa Pardo, BA (Hons)

Role: CONTACT

Vanessa.Pardo@nshealth.ca

902-473-2585

Facility Contacts

Dr. Abraham Nunes

Role: primary

Abraham.Nunes@nshealth.ca

902-473-2585

Other Identifiers

DALKETCLIN

Identifier Type: -

Identifier Source: org_study_id